Access the full text.
Sign up today, get DeepDyve free for 14 days.
K. Ramadan, J. Connors, A. Al-Tourah, K. Song, R. Gascoyne, M. Barnett, T. Nevill, J. Shepherd, S. Nantel, H. Sutherland, D. Forrest, D. Hogge, J. Lavoie, Y. Abou-Mourad, M. Chhanabhai, N. Voss, R. Brinkman, C. Smith, C. Toze (2008)
Allogeneic SCT for relapsed composite and transformed lymphoma using related and unrelated donors: long-term resultsBone Marrow Transplantation, 42
Roel Kampen, C. Canals, H. Schouten, A. Nagler, K. Thomson, J. Vernant, A. Buzyn, M. Boogaerts, J. Luan, S. Maury, N. Milpied, J. Jouet, G. Ossenkoppele, A. Sureda (2011)
Allogeneic stem-cell transplantation as salvage therapy for patients with diffuse large B-cell non-Hodgkin's lymphoma relapsing after an autologous stem-cell transplantation: an analysis of the European Group for Blood and Marrow Transplantation Registry.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 29 10
H. Guirguis, M. Cheung, E. Piliotis, D. Spaner, N. Berinstein, K. Imrie, Liying Zhang, R. Buckstein (2014)
Survival of patients with transformed lymphoma in the rituximab eraAnnals of Hematology, 93
B. Link, M. Maurer, G. Nowakowski, S. Ansell, W. Macon, S. Syrbu, S. Slager, C. Thompson, D. Inwards, P. Johnston, J. Colgan, T. Witzig, T. Habermann, J. Cerhan (2013)
Rates and outcomes of follicular lymphoma transformation in the immunochemotherapy era: a report from the University of Iowa/MayoClinic Specialized Program of Research Excellence Molecular Epidemiology Resource.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 31 26
Andrew Rezvani, B. Storer, M. Maris, M. Sorror, E. Agura, R. Maziarz, J. Wade, T. Chauncey, S. Forman, T. Lange, J. Shizuru, A. Langston, M. Pulsipher, B. Sandmaier, R. Storb, D. Maloney (2008)
Nonmyeloablative allogeneic hematopoietic cell transplantation in relapsed, refractory, and transformed indolent non-Hodgkin's lymphoma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 26 2
B. Oiffier, E. Epage, J. Rière, R. Erbrecht, T. Illy, R. Ouabdallah, P. Ierre, M. Orel, E. Este, G. Alles, P. Aulard, F. Eyes, C. Isselbrecht (2002)
CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell LymphomaThe New England Journal of Medicine, 346
S. Swerdlow (2017)
WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues
W Hiddemann, M Kneba, M Dreyling, N Schmitz, E Lengfelder, R Schmits, M Unterhalt (2005)
Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP aloneBlood, 106
J. Dongen, A. Langerak, M. Brüggemann, P. Evans, M. Hummel, F. Lavender, É. Delabesse, F. Davi, E. Schuuring, E. Schuuring, R. García-Sanz, J. Krieken, J. Droese, D. Gonzalez, C. Bastard, H. White, M. Spaargaren, Marcos González, A. Parreira, John Smith, Gareth Morgan, M. Kneba, E. Macintyre (2003)
Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: Report of the BIOMED-2 Concerted Action BMH4-CT98-3936Leukemia, 17
G. Salles, J. Seymour, F. Offner, A. López-Guillermo, D. Belada, L. Xerri, P. Feugier, R. Bouabdallah, J. Catalano, P. Brice, D. Caballero, C. Haioun, L. Pedersen, A. Delmer, D. Simpson, S. Leppa, P. Soubeyran, A. Hagenbeek, O. Casasnovas, T. Intragumtornchai, C. Fermé, Maria Silva, C. Sebban, A. Lister, J. Estell, G. Milone, A. Sonet, M. Mendila, B. Coiffier, H. Tilly (2011)
Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trialThe Lancet, 377
B. Cheson, B. Pfistner, M. Juweid, R. Gascoyne, L. Specht, S. Horning, B. Coiffier, R. Fisher, A. Hagenbeek, E. Zucca, S. Rosen, S. Stroobants, T. Lister, R. Hoppe, M. Dreyling, K. Tobinai, J. Vose, J. Connors, M. Federico, V. Diehl (2007)
Revised response criteria for malignant lymphoma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 25 5
Andrew Davies, A. Rohatiner, Sacha Howell, K. Britton, S. Owens, Ivana Micallef, D. Deakin, Bernadette Carrington, Jeremy Lawrance, S. Vinnicombe, S. Mather, J. Clayton, R. Foley, H. Jan, Stewart Kroll, Maggie Harris, J. Amess, A. Norton, T. Lister, John Radford (2004)
Tositumomab and iodine I 131 tositumomab for recurrent indolent and transformed B-cell non-Hodgkin's lymphoma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 22 8
S. Montoto, A. Davies, J. Matthews, M. Calaminici, A. Norton, J. Amess, S. Vinnicombe, R. Waters, A. Rohatiner, T. Lister (2007)
Risk and clinical implications of transformation of follicular lymphoma to diffuse large B-cell lymphoma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 25 17
M. Oers, R. Klasa, R. Marcus, M. Wolf, E. Kimby, R. Gascoyne, A. Jack, M. Veer, A. Vranovský, H. Holte, M. Glabbeke, I. Teodorović, Cynthia Rozewicz, A. Hagenbeek (2006)
Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial.Blood, 108 10
M. Eide, G. Lauritzsen, G. Kvalheim, A. Kolstad, U. Fagerli, M. Maisenhölder, B. Østenstad, Ø. Fluge, J. Delabie, H. Aarset, K. Liestøl, H. Holte (2011)
High dose chemotherapy with autologous stem cell support for patients with histologically transformed B‐cell non‐Hodgkin lymphomas. A Norwegian multi centre phase II studyBritish Journal of Haematology, 152
A. Al-Tourah, K. Gill, M. Chhanabhai, P. Hoskins, R. Klasa, K. Savage, L. Sehn, T. Shenkier, R. Gascoyne, J. Connors (2008)
Population-based analysis of incidence and outcome of transformed non-Hodgkin's lymphoma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 26 32
D. Villa, M. Crump, T. Panzarella, K. Savage, C. Toze, D. Stewart, D. Macdonald, R. Buckstein, Christina Lee, M. Alzahrani, M. Rubinger, R. Foley, A. Xenocostas, M. Sabloff, A. Muccilli, N. Chua, F. Couture, J. Larouche, S. Cohen, J. Connors, Kimberley Ambler, A. Al-Tourah, K. Ramadan, J. Kuruvilla (2013)
Autologous and allogeneic stem-cell transplantation for transformed follicular lymphoma: a report of the Canadian blood and marrow transplant group.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 31 9
R. Marcus, K. Imrie, A. Belch, D. Cunningham, E. Flores, J. Catalano, P. Solal-Céligny, F. Offner, J. Walewski, J. Raposo, A. Jack, Paul Smith (2005)
CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma.Blood, 105 4
K. Ardeshna, W. Qian, Paul Smith, Nivette Braganca, L. Lowry, P. Patrick, J. Warden, L. Stevens, C. Pocock, F. Miall, D. Cunningham, J. Davies, A. Jack, R. Stephens, J. Walewski, B. Ferhanoğlu, K. Bradstock, D. Linch (2014)
Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma: an open-label randomised phase 3 trial.The Lancet. Oncology, 15 4
M. Sabloff, H. Atkins, I. Bence‐Bruckler, C. Bredeson, D. Fergusson, P. Genest, H. Hopkins, B. Hutton, S. Mcdiarmid, L. Huebsch (2007)
A 15-year analysis of early and late autologous hematopoietic stem cell transplant in relapsed, aggressive, transformed, and nontransformed follicular lymphoma.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 13 8
Ir J Med Sci (2017) 186:589–595 DOI 10.1007/s11845-017-1594-z ORIGINAL ARTICLE Transformed follicular lymphoma (tFL): consolidation therapy may improve survival 1,2 2,3 1,2 1,2 1,2 • • • • • E. Elhassadi R. Flavin P. Browne E. Conneally P. Hayden 4 1 1,2 • • F. Quinn E. Higgins E. Vandenberghe Received: 30 August 2016 / Accepted: 2 March 2017 / Published online: 21 March 2017 Royal Academy of Medicine in Ireland 2017 Abstract presented with stage III/IV disease. Thirteen (50%) patients Purpose Retrospective study to evaluate the outcome of presented with de novo tFL and the remainder had previ- patients with transformed follicular lymphoma (tFL) trea- ously diagnosed FL, with a median time to transformation ted with rituximab-containing chemotherapy and of 5.7 (range 1–15) years. The median follow-up time from consolidation. tFL diagnosis to December 2015 is 8 (range 4–14) years. Patients and methods Patients diagnosed with tFL from All patients received immuno-chemotherapy achieving an 2003 to 2013 treated with consolidation therapy with last overall response rate (ORR) of 100%. Fourteen (54%), follow-up in December 2015 were identified from the patients were transplant eligible and based on donor institutional lymphoma database and included in this study. availability, six had
Irish Journal of Medical Science (1971 -) – Springer Journals
Published: Mar 21, 2017
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.